The U.S. Food and Drug Administration FDA is overhauling its top drug and biologics regulators, a move announced Tuesday that follows the sudden departure of former commissioner Marty Makary. The shakeup, described in an internal memo, includes shifts in leadership roles responsible for overseeing prescription drugs, vaccines, and medical devices. While the agency has not detailed the full scope of the changes, sources familiar with the matter say the reorganization aims to improve efficiency in drug approvals and post-market oversight.

Leadership vacuum at the FDA

Makary stepped down last week after less than two years in the role, citing personal reasons. His exit left a leadership gap at an agency grappling with a backlog of drug applications and mounting pressure from Congress to accelerate approvals for critical therapies. Janet Woodcock, a longtime FDA veteran, has been serving as acting commissioner in the interim. The new leadership shuffle appears designed to stabilize operations amid growing scrutiny over the agency’s handling of drug reviews and safety monitoring.

The FDA’s Center for Drug Evaluation and Research CDER and Center for Biologics Evaluation and Research CBER are central to the reorganization. Key positions such as the director of the Office of New Drugs and the deputy commissioner for medical products and tobacco are expected to see personnel changes. Industry analysts view the moves as an effort to address delays in approving generics and biosimilars, which have faced criticism from lawmakers and patient advocates.

Industry reaction and policy implications

Pharmaceutical trade groups have cautiously welcomed the leadership changes, emphasizing the need for predictable and timely regulatory decisions. The Biotechnology Innovation Organization BIO issued a statement calling for clarity on how the restructuring will impact approval timelines. Meanwhile, some consumer advocacy groups have raised concerns that the shakeup could further slow reviews of experimental treatments for rare diseases.

The FDA has not confirmed whether additional leadership changes are planned beyond the announced shuffle. Woodcock, who previously led CDER, is expected to play a key role in guiding the transition. Analysts suggest the reorganization may also reflect broader shifts in the agency’s approach to drug safety and innovation, particularly as it faces pressure to balance speed with rigorous oversight.

What happens next?

The FDA is expected to name permanent replacements for the affected roles in the coming weeks. Congressional hearings on drug approval backlogs are also anticipated, with lawmakers likely to question agency officials about the impact of the leadership changes. Meanwhile, industry stakeholders are monitoring the situation closely, as any delays in drug approvals could have ripple effects on patient access to new therapies.

For now, Woodcock remains the acting commissioner, overseeing a critical moment for the agency as it navigates both internal restructuring and external scrutiny. The FDA’s ability to maintain regulatory momentum while addressing staffing gaps will be closely watched by both the pharmaceutical industry and patient advocacy groups.

What You Need to Know

  • Source: CNBC
  • Published: May 16, 2026 at 01:42 UTC
  • Category: Business
  • Topics: #cnbc · #finance · #economy · #health · #fda · #medicine

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on CNBC →

All reporting rights belong to the respective author(s) at CNBC. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O Brasil, que há anos mira nos avanços regulatórios dos Estados Unidos para pautar suas próprias políticas de saúde, assiste agora a um rearranjo estratégico na Agência de Alimentos e Medicamentos (FDA) após a saída do influente comissário Marty Makary, um nome associado à desregulamentação e à aceleração de aprovações de fármacos.

A reestruturação promovida pela FDA, que remanejou os principais reguladores de medicamentos e biológicos, sinaliza não apenas uma mudança administrativa, mas também possíveis ajustes na abordagem das agências norte-americanas em relação à segurança e inovação farmacêutica — dois temas que sempre geram debates acalorados no Brasil, especialmente quando o país discute a implementação de novas tecnologias médicas ou a flexibilização de processos de registro. Para os brasileiros, o episódio serve como um lembrete de como as decisões em Washington podem reverberar em Brasília, influenciando desde a agenda da Anvisa até as discussões no Congresso sobre patentes e acesso a medicamentos.

Se a FDA optar por endurecer ou suavizar suas normas, o impacto global — e, inevitavelmente, o brasileiro — poderá ser sentido nos próximos anos, seja na velocidade com que novos tratamentos chegam ao mercado ou na forma como os sistemas de saúde pública se preparam para absorver essas inovações.

🇪🇸 Resumen en Español

La Agencia estadounidense del Medicamento (FDA) reajusta su equipo directivo en el área de fármacos y productos biológicos tras la salida de Marty Makary, una figura clave en la regulación farmacéutica. Este movimiento refleja cambios estratégicos en el organismo regulador más influyente del mundo, que podrían tener repercusiones globales en el acceso a medicamentos.

El reajuste responde a una necesidad de renovación interna y alineación con las prioridades sanitarias actuales, incluyendo la aceleración de la aprobación de tratamientos innovadores. Para los hispanohablantes, este cambio podría influir en la disponibilidad y precios de medicamentos en mercados como el latinoamericano, donde la FDA sirve como referencia regulatoria. Además, subraya la importancia de seguir de cerca las decisiones de la FDA, cuyas políticas impactan directamente en la industria farmacéutica global y, por tanto, en los consumidores.